Outcome of Board Meeting hel today i.e. 10th October 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 5.3 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Evoq Remedies' Board approved unaudited H1 FY26 results showing revenue from operations jumping to Rs 2,550.68 lakhs from Rs 1,175.67 lakhs in the prior half year, more than doubling. However, profit before tax collapsed to just Rs 7.88 lakhs from Rs 175.26 lakhs, and net profit fell to Rs 5.43 lakhs from Rs 171.26 lakhs, with EPS dropping to Rs 0.02. The auditor (H Thakkar & Co. LLP) issued a qualified review report flagging a SEBI investigation and show cause notice related to a Rs 9.21 crore preferential allotment, non-compliance with audit trail requirements under Section 178(5), unconfirmed supplier advances of Rs 1,250.87 lakhs, a Rs 655.03 lakh GST order, Rs 39.99 lakh disputed income tax demand, and Rs 668.86 lakhs in related-party loans made without proper compliance under Sections 177/185/186/188/189 of the Companies Act. Net cash from operating activities was deeply negative at Rs (1,462.30) lakhs.
Despite strong top-line growth, collapsing profits, a negative operating cash flow, and a long list of regulatory and audit qualifications — including a pending SEBI investigation — make this a high-risk filing for shareholders. Investors should watch for outcomes of the SEBI show cause notice and GST/IT litigation as these could materially affect the company's financial position.
| Q2 FY26 | Q2 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹25.51 Cr | ₹0.00 Cr | turned positive |
| Operating profit | −₹0.98 Cr | −₹1.64 Cr | loss narrowed |
| Profit after tax | — | — | — |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.